Your browser doesn't support javascript.
loading
Evolution of Early-Phase Anticancer Drug Investigations in China.
Wang, Shuhang; Yu, Yue; Jiang, Yale; Zhang, Huishan; Ma, Peiwen; Liu, Gang; Li, Ning.
Afiliação
  • Wang S; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Yu Y; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Jiang Y; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhang H; Phase I Clinical Trial Ward, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Province, China.
  • Ma P; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Liu G; Key Laboratory of Molecular Epigenetics of the Ministry of Education, Northeast Normal University, Changchun, China.
  • Li N; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
JAMA Oncol ; 8(11): 1692-1694, 2022 11 01.
Article em En | MEDLINE | ID: mdl-36074496
This study examines phase 1 anticancer drug clinical trials performed in China from 2017 to 2021.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article